Physician profile
Michael A Weitz
NPI 1639145337
$657,711.35
in general payments reported to CMS, 2019-2025
47 companies · $30K in 2025
The $30K reported for 2025 was more than what 94% of Rheumatology providers received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $291K · 2020: $99K · 2021: $69K · 2022: $84K · 2023: $51K · 2024: $34K · 2025: $30K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $91K · Travel and Lodging: $12K · Food and Beverage: $9,843 · Consulting Fee: $1,650 · Education: $106.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $91,469.50 |
| Travel and Lodging | $11,513.00 |
| Food and Beverage | $9,843.08 |
| Consulting Fee | $1,650.00 |
| Education | $105.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $224,898.90 | 2019-2025 | Evenity, Otezla, Tavneos |
| Lilly USA, LLC | $149,230.46 | 2019-2024 | Taltz |
| Janssen Scientific Affairs, LLC | $104,902.85 | 2019-2024 | Tremfya, Simponi Aria, Stelara |
| Janssen Biotech, INC. | $62,215.60 | 2019-2025 | Simponi Aria, Tremfya |
| Radius Health, INC. | $40,581.58 | 2019-2025 | |
| Celgene Corporation | $16,626.05 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $13,740.34 | 2019-2024 | Orencia |
| Novartis Pharmaceuticals Corporation | $13,152.02 | 2019-2025 | |
| Ucb, INC. | $11,134.32 | 2019-2025 | Cimzia, Bimzelx |
| Regeneron Healthcare Solutions, INC. | $6,297.56 | 2019 | |
| Genentech USA, INC. | $4,255.81 | 2019 | |
| Genzyme Corporation | $3,984.98 | 2019-2025 | |
| Abbvie INC. | $2,583.14 | 2019-2025 | Rinvoq, Skyrizi |
| Ani Pharmaceuticals, INC. | $911.58 | 2022-2025 | Purified Cortrophin Gel |
| Aurinia Pharma U.S., INC. | $451.04 | 2023-2025 | Lupkynis |
Show all 46 companies
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Weitz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.